Eli Lilly shares rise as GLP-1 sales extend lead over Novo Nordisk
Incretin franchise revenue was the driver behind the move in Lilly stock, according to the report.
TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: Yahoo Finance
The wire
- 01Eli Lilly stock climbed after GLP-1 sales widened the company's lead over rival Novo Nordisk.
- 02Incretin revenue share shapes which manufacturer controls supply, pricing and contracting for clinicians and dispensers of obesity and diabetes drugs.
- 03The item reports a share-price reaction; underlying volume, pricing and channel detail are needed to judge how durable the gap is.
From the source
Read at finance.yahoo.comEli Lilly stock jumps as GLP-1 sales widen Novo lead
